The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer (NSCLC), based on data from the CHRYSALIS trial (NCT02609776) presented at the 2021 American Society of Clinical Oncology Annual Meeting.
According to Spira, the safety profile of the combination is very different from chemotherapy. The major adverse events include rash and diarrhea. Additionally, amivantamab may cause infusion-related toxicities. However, according to Spira, the combination in well tolerated.
Changes in patients’ nails and hair are also common with the combination. Most infusion-related reactions occur in the first day, according to Spira, and generally do not continue for much longer.
